Current Report Filing (8-k)
May 22 2017 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 17,
2017
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
9171
Towne Centre Drive, Suite 440,
San Diego, CA
|
|
92122
|
|
(Address of
Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17
CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 8.01 – Other Events
On May 22, 2017, the Company issued a press release announcing that
it had entered into an exclusive license and distribution agreement
with Luminarie Pty Ltd., a company based in Australia for the
distribution of its Zestra® and Zestra Glide® products in
Australia, New Zealand and the Philippines. Pursuant to the
Luminarie agreement, Luminarie shall provide Innovus with an
up-front payment and it has minimum annual purchase requirements
for Zestra® and Zestra Glide® during the term of the
agreement.
The
full text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press release
issued May 22, 2017.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Date: May 22,
2017
|
By:
|
/s/
Bassam
Damaj
|
|
|
|
|
Bassam
Damaj
|
|
|
|
|
President and Chief Executive
Officer
|
|
EXHIBIT INDEX
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press release
issued May 22, 2017.
|